AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9673298 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Borrelia burgdorferi outer-surface lipoprotein A (OspA) with adjuvant
Number of subjects: 10936
Study 9673298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10936
Study 8078953 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine per day
Number of subjects: 24
Study 8078953 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg amitriptyline per day
Number of subjects: 24
Study 2688529 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 370 mgI/ml
Number of subjects: 24
Study 2688529 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate 320 mgI/ml
Number of subjects: 24
Study 164489 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive presleep condition
Number of subjects: 45
Study 164489 — intervention group
Group type: COMPARATOR
Intervention: Negative (stress) presleep condition
Number of subjects: 45
Study 164489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dreaming overtly or symbolically of the presleep laboratory situation
Number of subjects: 45
Study 29959901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives 1 (20μg EE/150μg desogestrel)
Number of subjects: 178
Study 29959901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives 2 (30μg EE/3mg drospirenone)
Number of subjects: 178
Study 29959901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study 29959901 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives 1 and 2
Number of subjects: 178
Study 28035636 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) over rVLPFC
Number of subjects: 79
Study 28035636 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 79
Study 26628523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain exposure physical therapy (PEPT)
Number of subjects: 56
Study 26628523 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 56
Study 23789215 — intervention group
Group type: COMPARATOR
Intervention: Blood-activating and damp-eliminating group
Number of subjects: 160
Study 23789215 — intervention group
Group type: COMPARATOR
Intervention: Invigorating and promoting Qi group
Number of subjects: 160
Study 23789215 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-combination stimulation group
Number of subjects: 160
Study 21671752 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI-C (dry powder inhaler with ∼10% less of each drug per metered dose)
Number of subjects: 19
Study 21671752 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI-C
Number of subjects: 19
Study 21671752 — intervention group
Group type: COMPARATOR
Intervention: DPI-A (Advair Diskus®, GlaxoSmithKline, delivering 100 μg fluticasone propionate and 50 μg salmeterol)
Number of subjects: 19
Study 18213738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (serotonin) depletion (ATD)
Number of subjects: 14
Study 18213738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine/phenylalanine (dopamine) depletion (ATPD)
Number of subjects: 14
Study 18213738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tryptophan/tyrosine/phenylalanine (CMD)
Number of subjects: 14
Study 18213738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced amino acid drink)
Number of subjects: 14
Study 16935126 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-modified cardiopulmonary bypass circuits
Number of subjects: 69
Study 16935126 — intervention group
Group type: COMPARATOR
Intervention: Standard unmodified circuit
Number of subjects: 69
Study 14612256 — intervention group
Group type: EXPERIMENTAL
Intervention: resident‐faculty
Number of subjects: 0
Study 14612256 — intervention group
Group type: COMPARATOR
Intervention: faculty‐faculty
Number of subjects: 0
Study 14612256 — intervention group
Group type: COMPARATOR
Intervention: resident‐faculty‐faculty
Number of subjects: 0
Study 11015169 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors)
Number of subjects: 0
Study 11015169 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower LDL cholesterol levels
Number of subjects: 0
Study 11015169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid‐lowering strategies
Number of subjects: 0
Study 8730243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg b.d.
Number of subjects: 18
Study 8730243 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg b.d.
Number of subjects: 18
Study 1382255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy (3 courses of chemotherapy with cisplatin 100 mg/m2, day 1 and etoposide 125 mg/m2 i.v., day 1; 250 mg/m2 p.o., day 2-3, followed by radiotherapy 4,000 cGy/20 fractions/4 weeks)
Number of subjects: 119
Study 1382255 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 119
Study 2580182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 12
Study 2580182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Propranolol
Number of subjects: 12
Study 2580182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Propranolol + Diuretic
Number of subjects: 12
Study 2580182 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Nifedipine
Number of subjects: 12
Study 2580182 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone
Number of subjects: 12
Study 31615803 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face training
Number of subjects: 0
Study 31615803 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 0
Study 31615803 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 30046837 — intervention group
Group type: EXPERIMENTAL
Intervention: MDCO-216 (20 mg/kg weekly for 5 weeks)
Number of subjects: 122
Study 30046837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 27377956 — intervention group
Group type: EXPERIMENTAL
Intervention: Seductive details
Number of subjects: 89
Study 27377956 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 25256180 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting
Number of subjects: 477
Study 25256180 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 477
Study 25256180 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite end point (any stroke, myocardial infarction, or death within 30 days or ipsilateral stroke in follow-up)
Number of subjects: 477
Study 25256180 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke and death
Number of subjects: 477
Study 22123525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpanthenol cream once daily (B)
Number of subjects: 0
Study 22123525 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min wIRA irradiation at 30 cm distance (C)
Number of subjects: 0
Study 22123525 — intervention group
Group type: EXPERIMENTAL
Intervention: wIRA irradiation for 30 min once daily together with dexpanthenol cream once daily (D)
Number of subjects: 0
Study 22123525 — intervention group
Group type: COMPARATOR
Intervention: No therapy (A)
Number of subjects: 0
Study 22123525 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (B-D)
Number of subjects: 0
Study 19925461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index (BIS) monitoring
Number of subjects: 26
Study 19925461 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 26
Study 18562739 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol 370
Number of subjects: 263
Study 18562739 — intervention group
Group type: COMPARATOR
Intervention: iodixanol 320
Number of subjects: 263
Study 15855263 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T(4) replacement
Number of subjects: 23
Study 15855263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 15855263 — intervention group
Group type: EXPERIMENTAL
Intervention: sHT patients
Number of subjects: 23
Study 12421103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 to 600mg followed by oral misoprostol 0.4 to 0.6mg or vaginal gemeprost 1.0mg/misoprostol 0.8mg
Number of subjects: 0
Study 12421103 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 0
Study 9474632 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial trivector approach
Number of subjects: 10
Study 9474632 — intervention group
Group type: COMPARATOR
Intervention: Standard medial parapatellar arthrotomy
Number of subjects: 10
Study 7618966 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0
Study 7618966 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 0
Study 2122251 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5000-unit bolus followed by continuous intravenous heparin)
Number of subjects: 205
Study 2122251 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (80 mg daily oral)
Number of subjects: 205
Study 386913 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 46
Study 386913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31957143 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult coloring pack
Number of subjects: 53
Study 31957143 — intervention group
Group type: COMPARATOR
Intervention: Placebo pack
Number of subjects: 53
Study 30857515 — intervention group
Group type: EXPERIMENTAL
Intervention: Î±-stat approach to ABG analysis
Number of subjects: 70
Study 30857515 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat approach to ABG analysis
Number of subjects: 70
Study 30857515 — intervention group
Group type: EXPERIMENTAL
Intervention: Î±-stat approach for randomised controlled trial
Number of subjects: 70
Study 30857515 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-stat approach for randomised controlled trial
Number of subjects: 70
Study 30021543 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening plus eave tubes (SET) + Long-Lasting Insecticidal Nets (LLINs)
Number of subjects: 200
Study 30021543 — intervention group
Group type: COMPARATOR
Intervention: Long-Lasting Insecticidal Nets (LLINs) only
Number of subjects: 200
Study 30021543 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening plus eave tubes (SET) + LLINs
Number of subjects: 200
Study 26967821 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 103
Study 25347623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 93
Study 25347623 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 93
Study 22157279 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg BID
Number of subjects: 183
Study 22157279 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 300 mg BID
Number of subjects: 183
Study 22157279 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride 750 mg BID
Number of subjects: 183
Study 20670323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mnemonic 44-55-66-PM
Number of subjects: 206
Study 20670323 — intervention group
Group type: COMPARATOR
Intervention: Control (classic description of OAR)
Number of subjects: 206
Study 17569792 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 100
Study 17569792 — intervention group
Group type: EXPERIMENTAL
Intervention: AirHeel brace
Number of subjects: 100
Study 17569792 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of eccentric training and AirHeel brace
Number of subjects: 100
Study 15788347 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy aimed at restoring dynamic stabilizing mechanisms and muscle co‐ordination at the shoulder
Number of subjects: 138
Study 15788347 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection
Number of subjects: 138
Study 15788347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical modalities and range of motion exercises
Number of subjects: 138
Study 11889011 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 0
Study 11889011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10077394 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 286
Study 10077394 — intervention group
Group type: COMPARATOR
Intervention: N-terminal proANP levels before PTCA
Number of subjects: 286
Study 10077394 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in N-terminal proANP from post-PTCA to final follow-up
Number of subjects: 286
Study 7627696 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 303
Study 7627696 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 303
Study 1790251 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 36
Study 1790251 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 36
Study 1790251 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin, 0.2 mg/kg, i.v. 24 h after birth
Number of subjects: 36
Study 1790251 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 36
Study 6759136 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 20
Study 6759136 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (100 mg in the morning plus 200 mg in the evening)
Number of subjects: 20
Study 6759136 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 20
Study 6759136 — intervention group
Group type: COMPARATOR
Intervention: Carprofen (100 mg 3 times daily)
Number of subjects: 20
Study 31284844 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit exercise training (25-75 minutes, three times per week for 12 weeks)
Number of subjects: 26
Study 31284844 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual daily lifestyle)
Number of subjects: 26
Study 28891835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan premedication
Number of subjects: 70
Study 28891835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25825410 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 12956
Study 24642379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ALT
Number of subjects: 234
Study 24642379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline AST
Number of subjects: 234
Study 24642379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Albumin
Number of subjects: 234
Study 24642379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Total Protein
Number of subjects: 234
Study 22786569 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ (50 mg losartan + 12.5 mg hydrochlorothiazide per day)
Number of subjects: 193
Study 22786569 — intervention group
Group type: COMPARATOR
Intervention: Maximal-dose ARB
Number of subjects: 193
Study 22786569 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/HCTZ
Number of subjects: 193
Study 20012639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 29
Study 20012639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 17728684 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16128944 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic management (control arm)
Number of subjects: 106
Study 12399289 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified isoflavone preparation (formulation A) with a genistein dose of 2, 4, 8, or 16 mg/kg body wt
Number of subjects: 24
Study 12399289 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified isoflavone preparation (formulation A)
Number of subjects: 24
Study 10191165 — intervention group
Group type: EXPERIMENTAL
Intervention: Multislice echo-planar imaging (EPI) with repetition times (TR) of 6.0, 3.0, and 1.5 s
Number of subjects: 0
Study 10191165 — intervention group
Group type: EXPERIMENTAL
Intervention: Slice thickness ranging from 1 to 8 mm
Number of subjects: 0
Study 7477218 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine every 12 hours
Number of subjects: 366
Study 7477218 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of zidovudine every 8 hours
Number of subjects: 366
Study 7477218 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of lamivudine every 12 hours plus zidovudine
Number of subjects: 366
Study 7477218 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine every 12 hours plus zidovudine
Number of subjects: 366
Study 2155751 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 units of intranasal calcitonin
Number of subjects: 40
Study 2155751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcitonin (1, 10, 100 units)
Number of subjects: 40
Study 2155751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7250475 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic retinoid Ro 10-9359 (AR) combined with PUVA therapy (schedule C)
Number of subjects: 126
Study 7250475 — intervention group
Group type: COMPARATOR
Intervention: PUVA therapy alone
Number of subjects: 126
Study 30488331 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from social media for up to one week (less if they 'broke' and resumed use)
Number of subjects: 415
Study 30488331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abstinence from social media)
Number of subjects: 415
Study 30488331 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (abstinence)
Number of subjects: 415
Study 30488331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abstinence)
Number of subjects: 415
Study 27692491 — intervention group
Group type: EXPERIMENTAL
Intervention: TD-intervention targeted patient-only
Number of subjects: 0
Study 27692491 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-intervention targeted patients and family members
Number of subjects: 0
Study 27692491 — intervention group
Group type: COMPARATOR
Intervention: Control - a handout on staying healthy during treatment
Number of subjects: 0
Study 26406079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation system using serious games
Number of subjects: 20
Study 26406079 — intervention group
Group type: COMPARATOR
Intervention: Control group (neurotypical development)
Number of subjects: 20
Study 23596089 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% discount on low-energy density fruits and vegetables (F&V), bottled water, and diet sodas
Number of subjects: 47
Study 21304815 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (En% P/C/F 65/5/30)
Number of subjects: 38
Study 21304815 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal (En% P/C/F 6/64/30)
Number of subjects: 38
Study 21304815 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 38
Study 21304815 — intervention group
Group type: COMPARATOR
Intervention: High-protein vs. high-carbohydrate meal
Number of subjects: 38
Study 21304815 — intervention group
Group type: EXPERIMENTAL
Intervention: Men vs. Women
Number of subjects: 38
Study 19286349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention for patients with SMI taking olanzapine
Number of subjects: 82
Study 19286349 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intervention for healthy controls
Number of subjects: 82
Study 18181382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 200 mg
Number of subjects: 552
Study 18181382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol Contramid OAD 300 mg
Number of subjects: 552
Study 18181382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 16765499 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (filled out the questionnaire four times during 6 months and received routine clinical care)
Number of subjects: 210
Study 16765499 — intervention group
Group type: COMPARATOR
Intervention: Control group (received routine clinical care only)
Number of subjects: 210
Study 16281465 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic laser treatment to the retina
Number of subjects: 1052
Study 16281465 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1052
Study 10917540 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted venous infusional 5-fluorouracil (PVI 5-FU) alone or PVI 5-FU and mitomycin C (MMC)
Number of subjects: 11
Study 8756915 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital chest images obtained with a selenium detector
Number of subjects: 104
Study 8756915 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiographs
Number of subjects: 104
Study 1382217 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic wardens (exposed group)
Number of subjects: 292
Study 1382217 — intervention group
Group type: COMPARATOR
Intervention: Hospital staff members (control group)
Number of subjects: 292
Study 3003305 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 3003305 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol
Number of subjects: 0
Study 3003305 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study 31607823 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) sessions offered weekly (VRidays) and access to high-end VR stations in the Nexus Reality Lab.
Number of subjects: 0
Study 27848017 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-interval, low-intensity, slow-jogging (SJ) program
Number of subjects: 81
Study 27848017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 26009595 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 800
Study 26009595 — intervention group
Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 800
Study 23604335 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 64